D. Ross Camidge, University of Colorado Anschutz Medical Campus (IMAGE)
Caption
D. Ross Camidge, MD, PhD and the ATOMIC consortium show that brigatinib remains effective even after first-line therapy with another next-generation ALK inhibitor.
Credit
University of Colorado Cancer Center
Usage Restrictions
None
License
Licensed content